Compare KRO & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRO | REPL |
|---|---|---|
| Founded | 1916 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 730.6M | 692.8M |
| IPO Year | 2004 | 2018 |
| Metric | KRO | REPL |
|---|---|---|
| Price | $6.38 | $7.19 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $6.00 | ★ $11.13 |
| AVG Volume (30 Days) | 379.1K | ★ 1.3M |
| Earning Date | 03-09-2026 | 02-03-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | ★ 5.25 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,859,400,000.00 | N/A |
| Revenue This Year | $3.47 | N/A |
| Revenue Next Year | $11.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.08 | $2.68 |
| 52 Week High | $7.90 | $13.24 |
| Indicator | KRO | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 63.28 | 46.67 |
| Support Level | $5.89 | $6.81 |
| Resistance Level | $6.74 | $8.82 |
| Average True Range (ATR) | 0.33 | 0.49 |
| MACD | 0.14 | 0.02 |
| Stochastic Oscillator | 88.28 | 31.47 |
Kronos Worldwide Inc manufactures and sells titanium dioxide pigments. Titanium dioxide is a white inorganic pigment used in various products. The majority of Kronos' sales come from titanium dioxide used for coatings on automobiles, aircraft, machines, appliances, traffic paint, and in both commercial and residential interiors and exteriors. The second product category is titanium dioxide used for plastics such as packaging materials and food packaging, houseware, appliances, toys, and computer cases. The maximum of revenue comes from the United States.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.